What Happened?
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
The investment bank increased its price target for Charles River to $195, citing signs that drug discovery cancellations had started to normalize and that bookings had stabilized. Analysts at the firm noted that checks suggested budgets at large pharmaceutical and bigger biotech companies were holding up. They also viewed the company hiring more staff to meet demand as a strong signal that management had confidence conditions would not worsen in the near term.
After the initial pop the shares cooled down to $173.81, up 2% from previous close.
Is now the time to buy Charles River Laboratories? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Charles River Laboratories’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 5.5% on the news that reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
Charles River Laboratories is down 4.8% since the beginning of the year, and at $173.81 per share, it is trading 21.2% below its 52-week high of $220.69 from November 2024. Investors who bought $1,000 worth of Charles River Laboratories’s shares 5 years ago would now be looking at an investment worth $759.41.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.